Remove market-access white-papers
article thumbnail

Moderna and UK government sign deal to establish mRNA facility

Pharmaceutical Technology

This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure. Additionally, the centre is anticipated to have to capacity to make up to 250 million doses of vaccines per year.

article thumbnail

Real world data reveal how diseases manifest in diverse populations

Clarivate

These conditions have mostly been studied in non-Hispanic White and Black individuals in the US, with few studies conducted on individuals of Hispanic ethnicity and other race/ethnicities. Such insights aid in gauging the market demand for newly developed medications. Davila, PhD, Senior Director, Epidemiology at Clarivate.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lilly and ProQR to expand genetic medicine development agreement

Pharmaceutical Technology

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. As per this deal, Lilly will obtain access to further targets in the central nervous system and peripheral nervous system using the Axiomer platform.

Medicine 131
article thumbnail

Kite and Daiichi Sankyo update cell therapy licensing agreement

Pharmaceutical Technology

According to the revised deal, Daiichi Sankyo and Kite will transfer the Marketing Authorization for Yescarta to Gilead’s Japan subsidiary, Gilead Sciences K.K., The therapy’s sales and promotion works in Japan following the transfer of marketing authorisation will be carried out by the Kite Cell Therapy Business Unit at Gilead Sciences K.K.

article thumbnail

New facility boosts UK’s cell and gene therapy manufacturing capacity

Pharmaceutical Technology

The representative expected the facility to open more treatment opportunities for UK citizens saying, “It will help give patients quick access to the latest treatments by increasing the number of UK patients with incurable diseases who are able to take part in clinical trials and bring new treatments into the NHS faster.”

article thumbnail

Kite and Arcellx enter partnership for multiple myeloma therapy development

Pharmaceutical Technology

The development, clinical trial and marketing expenses for the cell therapy will be shared by the companies while co-commercialising the product and equally splitting profits from the US region. Kite will oversee the marketing of the product outside the US while Arcellx is eligible for royalty payments on sales.

article thumbnail

AstraZeneca enters $320m deal to acquire Neogene

Pharmaceutical Technology

TCR-Ts can detect intracellular targets such as cancer-specific mutations to unlock targets which were not accessible earlier using cell therapies. The takeover will offer AstraZeneca access to TCR-Ts, which possess the potential for fighting solid tumours.